Madrigal Pharma (MDGL) Tops Q3 EPS by $1.84, Beats on Revenue

Madrigal Pharma (NASDAQ: MDGL) reported Q3 EPS of ($4.92), $1.84 better than the analyst estimate of ($6.76). Revenue for the quarter came in at $62.2 million versus the consensus estimate of $34.09 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty
• Blackstone Mortgage Trust (BXMT) PT Lowered to $20 at Keefe, Bruyette & Woods
• Wholesale Inventories (May P) 0.3% vs 0.4% Expected